

MS ENROLLMENT FORM



Connection • Care • Community

Greenhill Pharmacy | 2511 W 4th St, Wilmington, DE 19805 | Fax: 302-502-3885

PLEASE FAX: FOURTH STREET - 302-502-3885 • MARKET STREET - 302-513-9396

Patient Information

Patient Name _____
Address _____
Apt/Suite _____ City _____
State _____ Zip _____
Home Phone _____ Alternate Phone _____
DOB _____ SSN _____ Gender M F
Weight _____ kg/lbs Height _____ cm/in
Language Preference: English Spanish Other _____
Caregiver Name _____ Relation _____
Local Pharmacy _____ Phone _____
Insurance Plan _____ Plan ID _____

Please fax a copy of front and back of the insurance card(s)

Prescriber Information & Shipping Information

Prescriber's Name _____
NPI _____
Address _____
Apt/Suite _____ City _____
State _____ Zip _____
Contact _____
Phone _____ Alternate Phone _____
Fax _____
Email _____
If shipping to prescriber First Fill Always Never

Clinical Information (Please fax all pertinent clinical and lab information)

Diagnosis: G35 (Multiple Sclerosis) _____ Diagnosis Date: _____
Type: Clinically isolated syndrome Relapsing-remitting Secondary-progressive Primary-progressive Progressive-relapsing
Hepatic Impairment Present: Yes No AST: _____ U/L ALT: _____ U/L Bilirubin: _____ mg/dl Lab Date: _____
Pre-existing hepatic conditions: HBV HCV _____ TB Test: Positive Negative Test Date: _____
Prior Therapy Yes No Reason for Discontinuation of Therapy _____ Approximate Start Date _____ Approximate End Date _____

Comorbidities: _____
Concomitant Medications: _____
Allergies: NKDA Other: _____

Prescription Information

Drugs	Direction	Quantity	Refills	Drugs	Direction	Quantity	Refills
Ampyra®	To order Ampyra® please see the Acorda form at ampyra-hcp.com/local/files/acorda-service-request-form.pdf Phone: 888-881-1918 Fax: 888-883-3053			Gilenya® (fingolimod)	<input type="radio"/> Take 0.5 mg by mouth once daily	<input type="radio"/> 30x0.5 mg capsules	
Aubagio® (teriflunomide)	<input type="radio"/> Take 7 mg by mouth once daily <input type="radio"/> Take 14 mg by mouth once daily	<input type="radio"/> 28x7 mg tablets <input type="radio"/> 28x14 mg tablets		Glatopa™ (glatiramer acetate)	<input type="radio"/> Inject 20 mg subcut once daily	<input type="radio"/> 30x20 mg	
Avonex® (interferon beta-1a)	<input type="radio"/> Week 1: Inject 7.5 mcg (0.125 ml) intramuscularly once weekly; Week 2: Inject 15 mcg (0.25 ml) intramuscularly once weekly; Week 3: Inject 22.5 mcg (0.375 ml) intramuscularly once weekly; Week 4: Inject 30 mcg (0.5 ml) intramuscularly once weekly	<input type="radio"/> 4x30 mcg		Plegridy® (peginterferon beta-1a)	<input type="radio"/> Inject 63 mcg subcut on day 1; then inject 94 mcg on day 15 <input type="radio"/> Inject 125 mcg subcut on day 29 and every two weeks thereafter	<input type="radio"/> 1x63 mcg <input type="radio"/> 1x94 mcg <input type="radio"/> 2x125 mcg	
Betaseron® (interferon beta-1b)	<input type="radio"/> Week 1-2: Inject 0.0625 mg (0.25 ml) subcut every other day; Week 3-4: Inject 0.125 mg (0.5 ml) subcut every other day; <input type="radio"/> Week 5-6: Inject 0.1875 mg (0.75 ml) subcut every other day; Week 7-8: Inject 0.25 mg (1 ml) subcut every other day; <input type="radio"/> Inject 0.25 mg (1 ml) subcut every other day	<input type="radio"/> 14x0.3 mg <input type="radio"/> 14x0.3 mg <input type="radio"/> 14x0.3 mg		Rebif® (interferon beta-1a) Autoinjectors PFS	<input type="radio"/> Week 1-2: Inject 4.4 mcg (0.1 ml) subcut three times per week; Week 3-4: Inject 11 mcg (0.25 ml) subcut three times per week; Week 5 and thereafter: Inject 22 mcg subcut three times per week <input type="radio"/> Week 1-2: Inject 8.8 mcg (0.2 ml) subcut three times per week; Week 3-4: Inject 22 mcg (0.5 ml) subcut three times per week; Week 5 and thereafter: Inject 44 mcg subcut three times per week	<input type="radio"/> 6x8.8 mcg <input type="radio"/> 6x22 mcg <input type="radio"/> 12x22 mcg <input type="radio"/> 6x8.8 mcg <input type="radio"/> 6x22 mcg <input type="radio"/> 12x44 mcg	
Copaxone® (glatiramer acetate)	<input type="radio"/> Inject 20 mg subcut once daily <input type="radio"/> Inject 40 mg subcut three times per week at least 48 hours apart	<input type="radio"/> 30x20 mg <input type="radio"/> 12x40 mg		Tecfidera® (dimethyl fumarate)	<input type="radio"/> Take 120 mg by mouth twice daily for 7 days, then 240 mg by mouth twice daily thereafter. <input type="radio"/> Take 240 mg by mouth twice daily	<input type="radio"/> 30-day starter pack <input type="radio"/> 60x240 mg capsules	
Extavia® (interferon beta-1b)	<input type="radio"/> Week 1-2: Inject 0.0625 mg (0.25 ml) subcut every other day; Week 3-4: Inject 0.125 mg (0.5 ml) subcut every other day; <input type="radio"/> Week 5-6: Inject 0.1875 mg (0.75 ml) subcut every other day; Week 7 onward: Inject 0.25 mg (1 ml) subcut every other day; <input type="radio"/> Inject 0.25 mg (1 ml) subcut every other day	<input type="radio"/> 15x0.3 mg <input type="radio"/> 15x0.3 mg <input type="radio"/> 15x0.3 mg		Zinbryta™ (daclizumab)	To order, please see the Zinbryta™ forms at https://www.zinbrytarems.com/		

Injection Training Provided by: Physician's Office Pharmacy Other: _____

Per state-specific law, prescriptions will be dispensed as generic, if applicable, unless notated otherwise: _____

Ship to: Patient Office Other _____ Date _____ Needs by Date _____

*Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Prescriber's Signature: _____ Date: _____

PRODUCT SUBSTITUTION PERMITTED

DISPENSE AS WRITTEN

Supervising Physician / Supervising Physician Signature: _____

CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.